Immunotherapy targeting the PD-1/PD-L1 has been successful in advanced cervical cancer, but the potential clinical value of other checkpoint molecules remains unknown, such as TIM-3/LGALS9 or HLA-G/ILT2. This evidence concerns the gene HLA-G and cervical carcinoma.